Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Eligible age
18–50 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Sponsor: University Hospital, Clermont-Ferrand
You may qualify if…
- ✓ Cisgender women, premenopausal, aged 18 to 50 years.
- ✓ Cisgender men, aged 18 to 50 years.
- ✓ Diagnosed with migraine (according to ICHD-3 criteria).
- ✓ Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
- ✓ Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
- ✓ All routes of administration and all dosages.
- ✓ Affiliation with a social security system.
You may not qualify if…
- ✕ Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- ✕ Pregnant and breastfeeding women
Source: ClinicalTrials.gov · NCT07177885 · last updated 2026-03-09